Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24844592 | 0.82 | ALDH1A1 (0.31) | ALDH1A1POLBRAB9ANPC1 | |
| SCHEMBL9881652 | 0.79 | MAPK1 (0.45) | ALDH1A1LMNAMEN1TSHRKMT2A | |
| SCHEMBL3671626 | 0.76 | — | — | |
| SCHEMBL21341506 | 0.75 | HDAC1 (0.36) | NPSR1ALDH1A1HPGDHTTSMN1; SMN2 | |
| SCHEMBL29027809 | 0.74 | ALDH1A1 (0.34) | ALDH1A1POLBNPC1SMN1; SMN2MEN1 | |
| Potassium Ion SCHEMBL30281244 | 0.72 | HMGCR (0.34) | ALDH1A1POLBKDM4E | |
| SCHEMBL30282530 | 0.72 | HMGCR (0.36) | ALDH1A1POLB | |
| SCHEMBL9508815 | 0.72 | ALDH1A1 (0.33) | ALDH1A1POLB | |
| SCHEMBL14822692 | 0.70 | TDP1 (0.50) | ALDH1A1POLBHPGDHTTLMNA | |
| SCHEMBL14437465 | 0.67 | KDM4E (0.41) | NPSR1ALDH1A1RAB9ANPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10224485-B2 | Process for preparing a crystalline organic semiconductor material | BASF SE (DE) | 2019-03-05 | — | — | US | claimed |
| US-20170012208-A1 | ORGANIC SEMICONDUCTOR FORMULATIONS | USINVEST LLC | 2017-01-12 | — | — | US | claimed |
| EP-3183250-B1 | PROCESS FOR PREPARING CRYSTALLINE ORGANIC SEMICONDUCTOR MATERIAL | CLAP CO LTD (KR) | 2023-10-04 | — | — | EP | disclosed |
| EP-3183757-B1 | ORGANIC SEMICONDUCTOR COMPOSITION COMPRISING LIQUID MEDIUM | CLAP CO LTD (KR) | 2022-05-04 | — | — | EP | disclosed |
| CN-107004768-B | Organic semiconductor composition containing a liquid medium | 巴斯夫欧洲公司 | 2020-08-21 | — | — | CN | disclosed |
| US-10454037-B2 | Organic semiconductor composition comprising a liquid medium | BASF SE (DE) | 2019-10-22 | — | — | US | disclosed |
| US-10224485-B2 | Process for preparing a crystalline organic semiconductor material | BASF SE (DE) | 2019-03-05 | — | — | US | disclosed |
| US-10043978-B2 | Organic semiconductor formulations | FLEXTERRA, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-9873696-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-01-23 | — | — | US | disclosed |
| US-20170250347-A1 | ORGANIC SEMICONDUCTOR COMPOSITION COMPRISING A LIQUID MEDIUM | BASF SE (DE) | 2017-08-31 | — | — | US | disclosed |
| US-20170237005-A1 | PROCESS FOR PREPARING A CRYSTALLINE ORGANIC SEMICONDUCTOR MATERIAL | BASF SE (DE) | 2017-08-17 | — | — | US | disclosed |
| US-20170217959-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-08-03 | — | — | US | disclosed |
| EP-3183250-A1 | PROCESS FOR PREPARING CRYSTALLINE ORGANIC SEMICONDUCTOR MATERIAL | BASF SE (DE) | 2017-06-28 | — | — | EP | disclosed |
| EP-3183757-A1 | ORGANIC SEMICONDUCTOR COMPOSITION COMPRISING LIQUID MEDIUM | BASF SE (DE) | 2017-06-28 | — | — | EP | disclosed |
| US-20170012208-A1 | ORGANIC SEMICONDUCTOR FORMULATIONS | USINVEST LLC | 2017-01-12 | — | — | US | disclosed |
| US-9293711-B2 | Organic semiconductor formulations | POLYERA CORPORATION (US) | 2016-03-22 | — | — | US | disclosed |
| WO-2016027218-A1 | PROCESS FOR PREPARING CRYSTALLINE ORGANIC SEMICONDUCTOR MATERIAL | BASF SE (DE) | 2016-02-25 | — | — | WO | disclosed |
| WO-2016027217-A1 | ORGANIC SEMICONDUCTOR COMPOSITION COMPRISING LIQUID MEDIUM | BASF SE (DE) | 2016-02-25 | — | — | WO | disclosed |
| US-20140042369-A1 | Organic Semiconductor Formulations | USINVEST LLC | 2014-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170250347-A1 | ORGANIC SEMICONDUCTOR COMPOSITION COMPRISING A LIQUID MEDIUM | CRY1, NEFM, OR10J3 | NPSR1 3784/4885ALDH1A1 4298/4885POLB 1747/4885 |
| US-20170217959-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | NPSR1 25/4885ALDH1A1 2644/4885POLB 1730/4885 |
| US-10454037-B2 | Organic semiconductor composition comprising a liquid medium | CRY1, NEFM, OR10J3 | NPSR1 3784/4885ALDH1A1 4298/4885POLB 1747/4885 |
| US-10224485-B2 | Process for preparing a crystalline organic semiconductor material | STOM, SPOP, TTR | NPSR1 3127/4885ALDH1A1 4757/4885POLB 1829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.